Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia

European Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2003, Pages 189-193

  Kowalski, J ^a   Okopien B ^a   Madej, A ^a   Zielinski M ^a   Belowski, D ^a   Kalina, Z ^a   Herman, Z S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Atorvastatin; Fenofibrate; Hyperlipoproteinemia; MCP 1; Monocyte; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CELL ADHESION MOLECULE; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; INFLAMMATORY DISEASE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; CELLS, CULTURED; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; MONOCYTES; PROCETOFEN; PYRROLES; SIMVASTATIN;

EID: 0043165006     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0581-7     Document Type: Article

References (28)

1. Libby P, Hansson GK (1991) Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 64:5-15
2. Ross R (1991) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809
3. Takahashi M, Masuyama JI, Ikeda U et al. (1995) Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circ Res 76:750-757
4. Steinberg D, Lewis A (1997) Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 95:1062-1071
5. Yla-Herttuala S, Lipton BA, Rosenfeld ME et al. (1991) Expression of monocyte chemotactic protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-5256
6. Gosling J, Slaymaker S, Gu L et al. (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103:773-778
7. Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion formation in CCR2-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897
8. Madej A, Okopień B, Kowalski J et al. (1998) Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharm Ther 36:345-349
9. Abe Y, El Masri B, Kimball KT et al. (1998) Soluble adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 18:723-731
10. Hackman A, Abe Y, Insull W Jr et al. (1996) Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93:1334-1338
11. Kowalski J, Okopień B, Madej A, Makowiecka K, Zieliński M, Kalina Z, Herman ZS (2001) Levels of sICAM-1, sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa and IIb. Int J Clin Pharm Ther 39:48-52
12. Fruebis J, Gonzales V, Silvestre M, Palinski W (1997) Effect of probucol treatment on gene expression of VCAM-1, MCP-1 and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 17:1289-302
13. Weber C, Erl W, Weber KS, Weber PC (1999) Effect of oxidized low-density lipoprotein, lipid mediators and statins on vascular cell interactions. Clin Chem Lab Med 37:243-251
14. International Task Force for Prevention of Coronary Heart Disease (1992) Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendation of the European Atherosclerosis Society. Nutr Metab Cardiovasc Dis 2:113-156
15. Flo RW, Naess A, Lund-Johansen F, Maehle BO, Sjursen H, Lehmann V, Solberg CO (1991) Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies. J Immunol Methods 137:89-94
16. Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainer DJ (1999) Monocyte chemoattractant protein-1 but not tumor necrosis factor-α is correlated with monocyte infiltration in mouse lipid lesions. Circulation 99:2310-2316
17. Sakai M, Kobori S, Matsumura T et al. (1997) HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low-density lipoprotein. Atherosclerosis 133:51-59
18. Davies MJ, Thomas AC (1985) Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 53:363-373
19. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657-671
20. Libby P (1995) Molecular basis of acute coronary syndromes. Circulation 91:2844-2850
21. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP (1998) Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-194
22. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb 9:178-183
23. Rezaie-Majd A, Maca T, Bucek RA, Valant P, Muller M, Husslein P, Kashanipour A, Minar E, Baghestanian M (2002) Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22:1194-1199
24. Grip O, Janciauskiene S, Lindgren S (2002) Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 51:58-62
25. Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest 100:2671-2679
26. Pasceri V, Cheng SJ, Willerson JT, Yech ET, Chang J (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103:2531-2534
27. Bustos C, Hernandez-Presa MA, Ortego M et al. (1998) HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in rabbit model of atherosclerosis. J Am Coll Cardiol 32:2057-2064
28. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J (1999) Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147:253-261